Cancer Drug Shows Promise in Treating Early-Stage Alzheimer’s

Researchers discover IDO1 inhibitors can restore brain metabolism and improve cognitive function in preclinical models.

Studies reveal that IDO1 inhibitors, originally developed for cancer, can improve brain energy metabolism in Alzheimer's models.
Blocking IDO1 activity in mice restored memory and cognitive function, showing potential for human treatment.
The drug PF06840003 successfully crossed the blood-brain barrier and improved glucose metabolism in astrocytes.
Research indicates that targeting brain metabolism could be effective for multiple neurodegenerative diseases.
Human trials are needed to confirm these promising findings from preclinical studies.